Neuroimaging correlates of pain in Parkinson's disease: A systematic review of structural and resting-state fMRI studies.

J PainAug 25, 2026 (epub)
Clinical ResearchNeurology

Samwel Sylvester Msigwa, Given Kihaga, Qiu-Yan Yu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined neuroimaging studies to understand pain mechanisms in Parkinson's disease (PD). It included 432 PD patients with pain, 225 without pain, and 257 healthy controls. Key findings revealed structural changes like prefrontal cortical thinning and altered resting-state functional connectivity in pain-related networks, supporting a network-based framework for PD-related pain.

Key findings

  • Reduced putamen activity was negatively correlated with pain severity in PD patients.
  • Disrupted striatal-limbic connectivity was observed in patients with pain.
  • Increased connectivity in the raphe nucleus was positively associated with pain.
  • PDP showed reduced connectivity in pain-related networks compared to healthy controls.

Why it matters

Understanding the neuroimaging correlates of pain in Parkinson's disease can help clinicians recognize the underlying mechanisms of pain, potentially guiding more effective management strategies for this common non-motor symptom.

Source

PubMed · PMID 42641775

Published in J Pain. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.